Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study

• Published in: Vaccine Vol. 40; no. 39; pp. 5701 - 5708
• Main Authors: Wang, Xiaoqi, Deng, Yao, Zhao, Li, Wang, Lei, Fu, Zhenwang, Tang, Lin, Ye, Fei, Liu, Qianqian, Wang, Wenling, Wang, Siquan, Hu, Bo, Guan, Xuhua, Han, Zhuling, Tong, Yeqing, Rodewald, Lance E., Yin, Zundong, Tan, Wenjie, Wang, Fuzhen, Huang, Baoying
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 16.09.2022; Elsevier Limited; The Authors. Published by Elsevier Ltd
• Subjects: Adolescent; Adult; adverse effects; Allergy and Immunology; Antibodies, Viral; Biological products; China; Clinical trials; Cohort analysis; Cohort Studies; Coronaviruses; COVID-19; COVID-19 - prevention & control; COVID-19 infection; COVID-19 vaccines; COVID-19 Vaccines - adverse effects; cytopathogenicity; Disease transmission; Epidemics; Humans; Immune persistence; Immunization; Immunogenicity; Immunogenicity, Vaccine; immunoglobulins; Inactivated vaccine; International standards; Medical laboratories; Middle Aged; Neutralization; Observational studies; Questionnaires; Regression analysis; Replacement vaccine; Safety; Sample size; SARS-CoV-2; seroprevalence; Severe acute respiratory syndrome coronavirus 2; Vaccination; Vaccines; Vaccines, Inactivated - adverse effects; Young Adult; Beijing China; China; COVID-19; Safety; Immune persistence; Immunogenicity; Replacement vaccine; Inactivated vaccine

To mitigate a national shortage of WIBP-CorV COVID-19 vaccine, China’s regulator approved administering BBIBP-CorV after WIBP-CorV for completion of a primary series. In a pragmatic observational study, we compared immunogenicity and safety of a primary series of WIBP-CorV followed by BBIBP-CorV wit...